Kim Brosen

List of Publications by Year in descending order

276 papers	13,867 citations	15504 65 h-index	28297 105 g-index
294 all docs	294 docs citations	294 times ranked	10240 citing authors

#	Article	IF	Citations
1	Serum Vaccine Antibody Concentrations in Children Exposed to Perfluorinated Compounds. JAMA - Journal of the American Medical Association, 2012, 307, 391-7.	7.4	534
2	The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain, 1990, 42, 135-144.	4.2	403
3	CYP2D6 and CYP2C19 genotypeâ€based dose recommendations for antidepressants:â€¨a first step towards subpopulationâ€specific dosages. Acta Psychiatrica Scandinavica, 2001, 104, 173-192.	4.5	367
4	Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology, 1993, 45, 1211-1214.	4.4	348
5	The hypoalgesic effect of tramadol in relation to CYP2D6*. Clinical Pharmacology and Therapeutics, 1996, 60, 636-644.	4.7	346
6	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology, 1996, 51, 73-78.	1.9	284
7	Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain, 1999, 83, 85-90.	4.2	283
8	The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clinical Pharmacology and Therapeutics, 1992, 52, 547-552.	4.7	266
9	Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. European Journal of Clinical Pharmacology, 1996, 51, 289-295.	1.9	217
10	The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics, 2011, 21, 837-850.	1.5	216
11	The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics, 1992, 51, 278-287.	4.7	214
12	The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics and Genomics, 2002, 12, 473-478.	5.7	204
13	The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics and Genomics, 1995, 5, 335-346.	5.7	193
14	Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European Journal of Clinical Pharmacology, 1993, 44, 349-355.	1.9	192
15	Reduced Antibody Responses to Vaccinations in Children Exposed to Polychlorinated Biphenyls. PLoS Medicine, 2006, 3, e311.	8.4	182
16	Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clinical Pharmacology and Therapeutics, 1990, 48, 686-693.	4.7	175
17	Recent Developments in Hepatic Drug Oxidation. Clinical Pharmacokinetics, 1990, 18, 220-239.	3.5	167
18	In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food and Chemical Toxicology, 2002, 40, 609-616.	3.6	156

#	Article	IF	Citations
19	Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics, 1992, 51, 288-295.	4.7	149
20	Estimated exposures to perfluorinated compounds in infancy predict attenuated vaccine antibody concentrations at age 5-years. Journal of Immunotoxicology, 2017, 14, 188-195.	1.7	146
21	The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clinical Pharmacology and Therapeutics, 1991, 49, 18-23.	4.7	138
22	Breastfeeding as an Exposure Pathway for Perfluorinated Alkylates. Environmental Science & Technology, 2015, 49, 10466-10473.	10.0	138
23	Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. European Neuropsychopharmacology, 2001, 11, 275-283.	0.7	121
24	Serum Concentrations of Antibodies Against Vaccine Toxoids in Children Exposed Perinatally to Immunotoxicants. Environmental Health Perspectives, 2010, 118, 1434-1438.	6.0	121
25	The Analgesic Effect of Tramadol After Intravenous Injection in Healthy Volunteers in Relation to CYP2D6. Anesthesia and Analgesia, 2006, 102, 146-150.	2.2	119
26	Serum Vaccine Antibody Concentrations in Adolescents Exposed to Perfluorinated Compounds. Environmental Health Perspectives, 2017, 125, 077018.	6.0	118
27	Is Therapeutic Drug Monitoring a Case for Optimizing Clinical Outcome and Avoiding Interactions of the Selective Serotonin Reuptake Inhibitors?. Therapeutic Drug Monitoring, 2000, 22, 143-154.	2.0	115
28	Plasma Concentrations of Perfluoroalkyl Substances and Risk of Type 2 Diabetes: A Prospective Investigation among U.S. Women. Environmental Health Perspectives, 2018, 126, 037001.	6.0	113
29	Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics, 1986, 40, 543-549.	4.7	110
30	Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical Pharmacology and Therapeutics, 1991, 49, 609-617.	4.7	109
31	In Vivo Imaging of Human ¹¹C-Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses. Journal of Nuclear Medicine, 2016, 57, 1920-1926.	5.0	106
32	A fluvoxamine-caffeine interaction study. Pharmacogenetics and Genomics, 1996, 6, 213-222.	5.7	104
33	Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. European Journal of Clinical Pharmacology, 1986, 30, 679-684.	1.9	103
34	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*. Clinical Pharmacology and Therapeutics, 1995, 57, 670-677.	4.7	101
35	Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clinical Pharmacology and Therapeutics, 1994, 55, 518-527.	4.7	97
36	The European COPHES/DEMOCOPHES project: Towards transnational comparability and reliability of human biomonitoring results. International Journal of Hygiene and Environmental Health, 2014, 217, 653-661.	4.3	95

#	Article	IF	Citations
37	Impact of dietary exposure to food contaminants on the risk of Parkinson's disease. NeuroToxicology, 2008, 29, 584-590.	3.0	94
38	Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective -demethylation and reduces the hypoalgesic effect of tramadol. Clinical Pharmacology and Therapeutics, 2005, 77, 312-323.	4.7	92
39	The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation Polymorphism. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 335-344.	2.5	92
40	The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundamental and Clinical Pharmacology, 2010, 24, 517-524.	1.9	92
41	Impact of the CYP2D6 genotype on postâ€operative intravenous oxycodone analgesia. Acta Anaesthesiologica Scandinavica, 2010, 54, 232-240.	1.6	92
42	Association between prenatal exposure to perfluorinated compounds and symptoms of infections at age 1â€“4years among 359 children in the Odense Child Cohort. Environment International, 2016, 96, 58-64.	10.0	92
43	Clinical Pharmacology in Research, Teaching and Health Care. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 531-559.	2.5	91
44	Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry. Therapeutic Drug Monitoring, 1996, 18, 393-396.	2.0	89
45	Longitudinal Associations of Exposure to Perfluoroalkylated Substances in Childhood and Adolescence and Indicators of Adiposity and Glucose Metabolism 6 and 12 Years Later: The European Youth Heart Study. Diabetes Care, 2016, 39, 1745-1751.	8.6	87
46	First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics, 1988, 43, 400-406.	4.7	85
47	Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. European Journal of Clinical Pharmacology, 2006, 62, 513-521.	1.9	84
48	Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-120.	2.0	81
49	A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics and Genomics, 1995, 5, 312-317.	5.7	80
50	Drug Interactions and the Cytochrome P450 System. Clinical Pharmacokinetics, 1995, 29, 20-25.	3.5	79
51	Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants. Therapie, 2004, 59, 5-12.	1.0	79
52	Determination of Urinary Metabolites of Caffeine for the Assessment of Cytochrome P4501A2, Xanthine Oxidase, and N-Acetyltransferase Activity in Humans. Therapeutic Drug Monitoring, 1996, 18, 254-262.	2.0	79
53	Association between Perfluorinated Compound Exposure and Miscarriage in Danish Pregnant Women. PLoS ONE, 2015, 10, e0123496.	2.5	78
54	Serum Concentrations of Polyfluoroalkyl Compounds in Faroese Whale Meat Consumers. Environmental Science & Technology, 2008, 42, 6291-6295.	10.0	76

#	Article	IF	Citations
55	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European Journal of Clinical Pharmacology, 2010, 66, 1199-1205.	1.9	75
56	Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates. Journal of Immunotoxicology, 2016, 13, 270-273.	1.7	75
57	Severity of COVID-19 at elevated exposure to perfluorinated alkylates. PLoS ONE, 2020, 15, e0244815.	2.5	73
58	Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?. Pain, 1993, 53, 335-339.	4.2	72
59	Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. British Journal of Clinical Pharmacology, 1999, 48, 829-838.	2.4	72
60	Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. European Journal of Clinical Pharmacology, 2004, 60, 109-114.	1.9	71
61	The hypoalgesic effect of imipramine in different human experimental pain models. Pain, 1995, 60, 287-293.	4.2	70
62	In vitro Metabolism of Genistein and Tangeretin by Human and Murine Cytochrome P450s. Basic and Clinical Pharmacology and Toxicology, 2003, 93, 14-22.	0.0	70
63	Escitalopram in painful polyneuropathy: A randomized, placebo-controlled, cross-over trial. Pain, 2008, 139, 275-283.	4.2	70
64	Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European Journal of Clinical Pharmacology, 2011, 67, 693-700.	1.9	70
65	PFAS concentrations in plasma samples from Danish school children and their mothers. Chemosphere, 2015, 129, 203-209.	8.2	69
66	Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study. Clinical Pharmacology and Therapeutics, 2005, 77, 458-467.	4.7	68
67	The Pharmacogenetics of Tramadol. Clinical Pharmacokinetics, 2015, 54, 825-836.	3.5	66
68	A geneâ€“gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenetics and Genomics, 2013, 23, 526-534.	1.5	65
69	A Comprehensive Review of Drugâ€“Drug Interactions with Metformin. Clinical Pharmacokinetics, 2015, 54, 811-824.	3.5	65
70	Reproductive Function in a Population of Young Faroese Men with Elevated Exposure to Polychlorinated Biphenyls (PCBs) and Perfluorinated Alkylate Substances (PFAS). International Journal of Environmental Research and Public Health, 2018, 15, 1880.	2.6	63
71	Neurobehavioral deficits at age 7years associated with prenatal exposure to toxicants from maternal seafood diet. Neurotoxicology and Teratology, 2012, 34, 466-472.	2.4	62
72	The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. European Journal of Clinical Pharmacology, 1998, 54, 261-264.	1.9	60

#	Article	IF	Citations
73	Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*. Clinical Pharmacology and Therapeutics, 1997, 62, 279-286.	4.7	59
74	Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. European Journal of Clinical Pharmacology, 2005, 61, 491-497.	1.9	59
75	Associations of maternal exposure to organophosphate and pyrethroid insecticides and the herbicide 2,4-D with birth outcomes and anogenital distance at 3 months in the Odense Child Cohort. Reproductive Toxicology, 2018, 76, 53-62.	2.9	59
76	Maternal urinary concentrations of pyrethroid and chlorpyrifos metabolites and attention deficit hyperactivity disorder (ADHD) symptoms in 2-4-year-old children from the Odense Child Cohort. Environmental Research, 2019, 176, 108533.	7.5	59
77	Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department. European Journal of Clinical Pharmacology, 1988, 34, 83-86.	1.9	58
78	Lack of effect of mianserin on the symptoms of diabetic neuropathy. European Journal of Clinical Pharmacology, 1992, 43, 251-255.	1.9	57
79	Imipramine and pregabalin combination for painful polyneuropathy. Pain, 2015, 156, 958-966.	4.2	57
80	A Comparative Pharmacokinetic Study in Healthy Volunteers of the Effect of Carbamazepine and Oxcarbazepine on Cyp3a4. Epilepsia, 2007, 48, 490-496.	5.1	56
81	Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. British Journal of Clinical Pharmacology, 1999, 48, 395-401.	2.4	55
82	Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone, 2018, 112, 35-41.	2.9	55
83	Structural equation modeling of immunotoxicity associated with exposure to perfluorinated alkylates. Environmental Health, 2015, 14, 47.	4.0	53
84	Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians*. Clinical Pharmacology and Therapeutics, 1996, 59, 304-311.	4.7	52
85	Perfluorohexane Sulfonate (PFHxS) and a Mixture of Endocrine Disrupters Reduce Thyroxine Levels and Cause Antiandrogenic Effects in Rats. Toxicological Sciences, 2018, 163, 579-591.	3.1	52
86	Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. European Journal of Clinical Pharmacology, 1998, 54, 427-430.	1.9	50
87	Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. European Neuropsychopharmacology, 1999, 9, 453-459.	0.7	50
88	Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. European Journal of Clinical Pharmacology, 2015, 71, 691-697.	1.9	50
89	Pharmacokinetic Interaction between Rifampin and the Combination of Indinavir and Lowâ€Dose Ritonavir in HIVâ€Infected Patients. Clinical Infectious Diseases, 2004, 38, 426-429.	5.8	49
90	Shorter duration of breastfeeding at elevated exposures to perfluoroalkyl substances. Reproductive Toxicology, 2017, 68, 164-170.	2.9	47

#	Article	IF	Citations
91	Acute hypoxia and cytochrome P450â€“mediated hepatic drug metabolism in humans. Clinical Pharmacology and Therapeutics, 2002, 71, 214-220.	4.7	46
92	The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clinical Pharmacology and Therapeutics, 1999, 66, 636-641.	4.7	45
93	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clinical Pharmacology and Therapeutics, 2001, 69, 41-47.	4.7	44
94	Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. Diabetologia, 2019, 62, 1251-1256.	6.3	43
95	Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of Guinea-Bissau Children. Environmental Health Perspectives, 2020, 128, 87002.	6.0	43
96	Griseofulvin and Fluvoxamine Interactions with the Metabolism of Theophylline. Therapeutic Drug Monitoring, 1997, 19, 56-62.	2.0	43
97	Association between perfluoroalkyl substance exposure and asthma and allergic disease in children as modified by MMR vaccination. Journal of Immunotoxicology, 2017, 14, 39-49.	1.7	41
98	Prenatal exposure to perfluoroalkyl substances and anogenital distance at 3 months of age in a Danish mother-child cohort. Reproductive Toxicology, 2017, 68, 200-206.	2.9	41
99	Codeine in post-operative pain. European Journal of Clinical Pharmacology, 1998, 54, 451-454.	1.9	40
100	A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: Number needed to treat versus postponement of hip fracture. Clinical Therapeutics, 2003, 25, 2575-2585.	2.5	40
101	Extremely Slow Metabolism of Amitriptyline but Normal Metabolism of Imipramine and Desipramine in an Extensive Metabolizer of Sparteine, Debrisoquine, and Mephenytoin. Therapeutic Drug Monitoring, 1991, 13, 177-182.	2.0	39
102	The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta-analysis. European Journal of Clinical Pharmacology, 1997, 51, 389-393.	1.9	39
103	Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. European Journal of Clinical Pharmacology, 1998, 54, 735-740.	1.9	39
104	Effect of hemoglobin adjustment on the precision of mercury concentrations in maternal and cord blood. Environmental Research, 2014, 132, 407-412.	7.5	39
105	Perfluoroalkyl substances and glycemic status in pregnant Danish women: The Odense Child Cohort. Environment International, 2018, 116, 101-107.	10.0	39
106	Associations of Exposure to Perfluoroalkyl Substances With Thyroid Hormone Concentrations and Birth Size. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 735-745.	3.6	39
107	A randomised, doubleâ€blind, placeboâ€controlled trial of metformin on myocardial efficiency in insulinâ€resistant chronic heart failure patients without diabetes. European Journal of Heart Failure, 2020, 22, 1628-1637.	7.1	39
108	The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. British Journal of Clinical Pharmacology, 2006, 62, 682-689.	2.4	38

#	Article	IF	Citations
109	CYP2D6 genotype determination in the Danish population. European Journal of Clinical Pharmacology, 1994, 47, 221-225.	1.9	37
110	Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. European Journal of Clinical Pharmacology, 2009, 65, 887-894.	1.9	37
111	Concomitant Intake of Nortriptyline and Carbamazepine. Therapeutic Drug Monitoring, 1993, 15, 258-260.	2.0	36
112	Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. British Journal of Clinical Pharmacology, 1997, 43, 253-258.	2.4	36
113	Effect of fluvoxamine on the pharmacokinetics of quinidine. European Journal of Clinical Pharmacology, 1999, 55, 451-456.	1.9	36
114	Lack of Association of OPRM1 and ABCB1 Singleâ€Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. Journal of Clinical Pharmacology, 2012, 52, 234-242.	2.0	36
115	Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 199-204.	2.5	36
116	Dermal uptake and percutaneous penetration of organophosphate esters in a human skin exÂvivo model. Chemosphere, 2018, 197, 185-192.	8.2	36
117	Fluvoxamine is a Potent Inhibitor of the Metabolism of Caffeine in vitro. Basic and Clinical Pharmacology and Toxicology, 1998, 83, 240-245.	0.0	35
118	The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. British Journal of Clinical Pharmacology, 2006, 61, 49-57.	2.4	35
119	The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARÎ³ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenetics and Genomics, 2013, 23, 219-227.	1.5	35
120	Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. American Journal of Physiology - Renal Physiology, 2015, 309, F235-F241.	2.7	35
121	Exposure to perfluoroalkyl substances during fetal life and hospitalization for infectious disease in childhood: A study among 1,503 children from the Odense Child Cohort. Environment International, 2021, 149, 106395.	10.0	35
122	Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clinical Pharmacology and Therapeutics, 2000, 68, 199-209.	4.7	34
123	Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clinical Pharmacology and Therapeutics, 2002, 71, 162-168.	4.7	34
124	A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). European Journal of Clinical Pharmacology, 2011, 67, 1131-1137.	1.9	34
125	PCB Concentrations and Dioxinâ€like Activity in Blood Samples from Danish School Children and Their Mothers living in Urban and Rural Areas. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 134-144.	2.5	33
126	Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography. Biomedical Applications, 1994, 660, 103-110.	1.7	32

#	Article	IF	Citations
127	Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes, Obesity and Metabolism, 2018, 20, 1593-1601.	4.4	32
128	Intake of <scp>S</scp>t <scp>J</scp>ohn's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. British Journal of Clinical Pharmacology, 2015, 79, 298-306.	2.4	31
129	CYP2D6 Polymorphism in Relation to Tramadol Metabolism: A Study of Faroese Patients. Therapeutic Drug Monitoring, 2008, 30, 271-275.	2.0	30
130	Prenatal exposure to persistent organochlorine pollutants is associated with high insulin levels in 5-year-old girls. Environmental Research, 2015, 142, 407-413.	7.5	30
131	Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls. European Journal of Clinical Pharmacology, 2006, 62, 1041-1048.	1.9	29
132	Increased Serum Concentrations of Persistent Organic Pollutants among Prediabetic Individuals: Potential Role of Altered Substrate Oxidation Patterns. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1705-E1713.	3.6	29
133	Rifampicin Treatment Greatly Increases the Apparent Oral Clearance of Qninidine. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 257-262.	0.0	28
134	Exposure to perfluoroalkyl substances and blood pressure in pregnancy among 1436 women from the Odense Child Cohort. Environment International, 2021, 151, 106442.	10.0	28
135	Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4*. Clinical Pharmacology and Therapeutics, 1997, 61, 319-324.	4.7	27
136	High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. Biomedical Applications, 1993, 612, 87-94.	1.7	26
137	Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. Diabetologia, 2015, 58, 2494-2502.	6.3	26
138	Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. European Journal of Clinical Pharmacology, 2001, 57, 123-127.	1.9	24
139	Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain. Clinical Pharmacology and Therapeutics, 2009, 86, 626-633.	4.7	24
140	GWAS-based association betweenRWDD3andTECTAvariants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta OncolÃ³gica, 2013, 52, 871-873.	1.8	24
141	Public health benefits of hair-mercury analysis and dietary advice in lowering methylmercury exposure in pregnant women. Scandinavian Journal of Public Health, 2017, 45, 444-451.	2.3	24
142	Prenatal Exposures to Perfluoroalkyl Acids and Associations with Markers of Adiposity and Plasma Lipids in Infancy: An Odense Child Cohort Study. Environmental Health Perspectives, 2020, 128, 77001.	6.0	24
143	Nonlinear Kinetics of Imipramine in Low and Medium Plasma Level Ranges. Therapeutic Drug Monitoring, 1990, 12, 445-449.	2.0	23
144	Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. Biomedical Applications, 1996, 676, 169-174.	1.7	23

#	Article	IF	Citations
145	Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. European Journal of Clinical Pharmacology, 1999, 55, 375-382.	1.9	23
146	Enantioselective HPLC method for quantitative determination of tramadol andO-desmethyltramadol in plasma and urine: Application to clinical studies. Chromatographia, 2003, 57, 279-285.	1.3	23
147	Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. British Journal of Clinical Pharmacology, 2018, 84, 510-519.	2.4	23
148	Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives. Psychoneuroendocrinology, 2019, 99, 183-190.	2.7	23
149	Exposure to perfluoroalkylated substances (PFAS) in relation to fitness, physical activity, and adipokine levels in childhood: The european youth heart study. Environmental Research, 2020, 191, 110110.	7.5	23
150	Quantitative Determination of Tolbutamide and Its Metabolites in Human Plasma and Urine by High-Performance Liquid Chromatography and UV Detection. Therapeutic Drug Monitoring, 1999, 21, 664.	2.0	23
151	Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenetics and Genomics, 2008, 18, 209-212.	1.5	22
152	Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. European Journal of Pharmaceutical Sciences, 2017, 99, 337-342.	4.0	22
153	HPLC Method for Determination of Rosiglitazone in Plasma. Chromatographia, 2005, 62, 197-201.	1.3	21
154	Consumption of Charcoal-Broiled Meat as an Experimental Tool for Discerning CYP1A2-Mediated Drug Metabolism in vivo. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 141-148.	2.5	21
155	Pregnancy Exposure to Perfluoroalkyl Substances and Associations With Prolactin Concentrations and Breastfeeding in the Odense Child Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e631-e642.	3.6	21
156	Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicology and Applied Pharmacology, 2007, 224, 202-206.	2.8	20
157	The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. British Journal of Clinical Pharmacology, 2008, 65, 134-138.	2.4	20
158	Quantitation of Metformin in Human Plasma and Urine by Hydrophilic Interaction Liquid Chromatography and Application to a Pharmacokinetic Study. Therapeutic Drug Monitoring, 2014, 36, 211-217.	2.0	20
159	Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60â€yearâ€old Caucasian woman with ovarian carcinoma. British Journal of Clinical Pharmacology, 2016, 81, 313-315.	2.4	20
160	Pâ€Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. Clinical Pharmacology and Therapeutics, 2020, 108, 671-680.	4.7	20
161	Interaction between tramadol and phenprocoumon. Lancet, The, 1997, 350, 637.	13.7	19
162	Quantification of morphine, morphine 6-glucuronide, buprenorphine, and the enantiomers of methadone by enantioselective mass spectrometric chromatography in whole blood. Forensic Science, Medicine, and Pathology, 2015, 11, 193-201.	1.4	19

#	Article	IF	Citations
163	N-acetyl-4-aminophenol (paracetamol) in urine samples of 6â€“11-year-old Danish school children and their mothers. International Journal of Hygiene and Environmental Health, 2015, 218, 28-33.	4.3	19
164	Associations between plasma concentrations of PCB 28 and possible indoor exposure sources in Danish school children and mothers. Environment International, 2016, 87, 13-19.	10.0	19
165	Early Life Exposures to Perfluoroalkyl Substances in Relation to Adipokine Hormone Levels at Birth and During Childhood. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5338-5348.	3.6	19
166	Hepatic exposure of metformin in patients with nonâ€alcoholic fatty liver disease. British Journal of Clinical Pharmacology, 2019, 85, 1761-1770.	2.4	19
167	Association between prenatal exposure to perfluoroalkyl substances and asthma in 5-year-old children in the Odense Child Cohort. Environmental Health, 2019, 18, 97.	4.0	19
168	Joint and independent neurotoxic effects of early life exposures to a chemical mixture. Environmental Epidemiology, 2019, 3, e063.	3.0	19
169	Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method. Analytical Biochemistry, 1990, 189, 99-102.	2.4	18
170	Sparteine and mephenytoin oxidation: Genetic polymorphisms in East and West Greenland. Clinical Pharmacology and Therapeutics, 1991, 49, 624-631.	4.7	18
171	Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. Nordic Journal of Psychiatry, 1993, 47, 21-26.	1.3	18
172	Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. Biomedical Applications, 1998, 712, 183-191.	1.7	18
173	Expression of two drugâ€metabolizing cytochrome P450â€enzymes in human salivary glands. Oral Diseases, 2008, 14, 533-540.	3.0	18
174	Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadolâ€™s O-demethylation via CYP2D6. European Journal of Clinical Pharmacology, 2010, 66, 655-660.	1.9	18
175	Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. Clinical Pharmacology and Therapeutics, 2021, 109, 150-159.	4.7	18
176	The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. European Journal of Clinical Pharmacology, 2006, 62, 437-445.	1.9	17
177	Probe Depth Matters in Dermal Microdialysis Sampling of Benzoic Acid after Topical Application: An ex vivo Study in Human Skin. Skin Pharmacology and Physiology, 2012, 25, 9-16.	2.5	17
178	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics, 2015, 16, 929-937.	1.3	17
179	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology, 2019, 84, 791-798.	2.3	17
180	Serum vaccine antibody concentrations in adults exposed to per- and polyfluoroalkyl substances: A birth cohort in the Faroe Islands. Journal of Immunotoxicology, 2021, 18, 85-92.	1.7	17

#	Article	IF	Citations
181	Life-course Exposure to Perfluoroalkyl Substances in Relation to Markers of Glucose Homeostasis in Early Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2495-2504.	3.6	17
182	High-Performance Liquid Chromatography of Clomipramine and Metabolites in Human Plasma and Urine. Therapeutic Drug Monitoring, 1993, 15, 122-128.	2.0	16
183	Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. British Journal of Clinical Pharmacology, 2003, 55, 100-106.	2.4	16
184	A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenetics and Genomics, 2015, 25, 259-262.	1.5	16
185	Concentrations of tetanus and diphtheria antibodies in vaccinated Greenlandic children aged 7â€“12 years exposed to marine pollutants, a cross sectional study. Environmental Research, 2022, 203, 111712.	7.5	16
186	The Danish contribution to the European DEMOCOPHES project: A description of cadmium, cotinine and mercury levels in Danish mother-child pairs and the perspectives of supplementary sampling and measurements. Environmental Research, 2015, 141, 96-105.	7.5	15
187	A Dual Label Oligonucleotide Ligation Assay for Detection of theCYP2C19*1, CYP2C19*2, and CYP2C19*3 Alleles Involving Time-Resolved Fluorometry. Therapeutic Drug Monitoring, 1998, 20, 1-6.	2.0	15
188	Dextropropoxyphene kinetics after single and repeated oral doses in man. European Journal of Clinical Pharmacology, 1985, 29, 79-84.	1.9	14
189	Drug Metabolism and Genetic Polymorphism in Subjects with Previous Halothane Hepatitis. Scandinavian Journal of Gastroenterology, 1993, 28, 677-680.	1.5	14
190	The <scp>ABCB</scp>1, rs9282564, <scp>AG</scp> and <scp>TT</scp> Genotypes and the <scp>COMT</scp>, rs4680, <scp>AA</scp> Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 381-388.	2.5	14
191	The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. Drugs in R and D, 2017, 17, 279-286.	2.2	14
192	Public-health risks from tea drinking: Fluoride exposure. Scandinavian Journal of Public Health, 2022, 50, 355-361.	2.3	14
193	Residential exposure to air pollution and access to neighborhood greenspace in relation to hair cortisol concentrations during the second and third trimester of pregnancy. Environmental Health, 2021, 20, 11.	4.0	14
194	No association between maternal and child PFAS concentrations and repeated measures of ADHD symptoms at age 2Â½ and 5 years in children from the Odense Child Cohort. Neurotoxicology and Teratology, 2021, 88, 107031.	2.4	14
195	Pharmacogenomics and migraine: possible implications. Journal of Headache and Pain, 2008, 9, 13-18.	6.0	13
196	Impaired Glucose Tolerance in Healthy Men Treated with St. John's Wort. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 219-224.	2.5	13
197	Clinical Pharmacology in Denmark in 2016 â€“ 40 Years with the Danish Society of Clinical Pharmacology and 20 Years as a Medical Speciality. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 523-532.	2.5	12
198	Prenatal exposure to pyrethroid and organophosphate insecticides and language development at age 20â€“36 months among children in the Odense Child Cohort. International Journal of Hygiene and Environmental Health, 2021, 235, 113755.	4.3	12

#	Article	IF	Citations
199	Determination of Theophylline Metabolites in Human Liver Microsomes by High-Performance Liquid Chromatography. Analytical Biochemistry, 1994, 222, 9-13.	2.4	11
200	Clinically important interaction between azathioprine (Imurel) and phenprocoumon (Marcoumar). European Journal of Clinical Pharmacology, 1997, 52, 503-504.	1.9	11
201	CYP2D6 polymorphism in systemic lupus erythematosus patients. European Journal of Clinical Pharmacology, 1999, 55, 21-25.	1.9	11
202	Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. European Journal of Clinical Pharmacology, 2012, 68, 1463-1464.	1.9	11
203	A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers. European Journal of Clinical Pharmacology, 2013, 69, 1997-1999.	1.9	11
204	Open letter on access to the BIA 10-2474 clinical trial data. Lancet, The, 2017, 389, 156.	13.7	11
205	Prenatal exposure to perfluorodecanoic acid is associated with lower circulating concentration of adrenal steroid metabolites during mini puberty in human female infants. The Odense Child Cohort. Environmental Research, 2020, 182, 109101.	7.5	11
206	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A singleâ€Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. Clinical Pharmacology and Therapeutics, 2021, 110, 1329-1336.	4.7	11
207	Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. British Journal of Clinical Pharmacology, 1999, 48, 663-668.	2.4	10
208	Cytochrome P4502C9 (CYP2C9) Genotypes in a Nordic Population in Denmark. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 151-152.	2.5	10
209	Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. European Journal of Clinical Pharmacology, 2010, 66, 1189-1197.	1.9	9
210	The inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of theCYP2C19*17allele. Clinical and Experimental Pharmacology and Physiology, 2013, 40, n/a-n/a.	1.9	9
211	CYP2C19*17 increases clopidogrelâ€mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 870-878.	1.9	9
212	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxelâ€"Letter. Clinical Cancer Research, 2015, 21, 3092-3093.	7.0	9
213	Limited sampling strategy for determining metformin area under the plasma concentrationâ€"time curve. British Journal of Clinical Pharmacology, 2016, 82, 1002-1010.	2.4	9
214	Initiation of glucoseâ€lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a selfâ€controlled register study. Journal of Thrombosis and Haemostasis, 2016, 14, 129-133.	3.8	9
215	Perfluoroalkyl Substance Exposure Early In Pregnancy Was Negatively Associated With Late Pregnancy Cortisone Levels. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2834-e2844.	3.6	9
216	Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: A large prospective trial. British Journal of Clinical Pharmacology, 2021, 87, 1963-1969.	2.4	9

#	Article	IF	Citations
217	Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study. Pharmacogenetics and Genomics, 1996, 6, 513-519.	5.7	8
218	Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?. Journal of Oral Pathology and Medicine, 2010, 39, 497-505.	2.7	8
219	Early Discontinuation of Metformin in Individuals Treated with Inhibitors of Transporters of Metformin. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 487-495.	2.5	8
220	Maternal exposure to perfluoroalkyl chemicals and anogenital distance in the offspring: A Faroese cohort study. Reproductive Toxicology, 2021, 104, 52-57.	2.9	8
221	Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. European Journal of Clinical Pharmacology, 1996, 49, 503-509.	1.9	8
222	Blood Harmane (1-Methyl-9H-Pyrido[3,4-b]indole) and Mercury in Essential Tremor: A Population-Based, Environmental Epidemiology Study in the Faroe Islands. Neuroepidemiology, 2020, 54, 272-280.	2.3	8
223	Expressing effects of osteoporosis interventions in terms of postponing of fractures. European Journal of Clinical Pharmacology, 2002, 58, 629-633.	1.9	7
224	Associations between exposure to perfluoroalkyl substances and body fat evaluated by DXA and MRI in 109 adolescent boys. Environmental Health, 2021, 20, 73.	4.0	7
225	Long-term residential exposure to air pollution is associated with hair cortisol concentration and differential leucocyte count in Flemish adolescent boys. Environmental Research, 2021, 201, 111595.	7.5	7
226	[20] Imipramine: A model drug for P450 research. Methods in Enzymology, 1996, 272, 177-186.	1.0	6
227	Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. Drug Metabolism and Personalized Therapy, 2015, 30, 147-163.	0.6	6
228	Within-person reproducibility of red blood cell mercury over a 10- to 15-year period among women in the Nursesâ€™ Health Study II. Journal of Exposure Science and Environmental Epidemiology, 2016, 26, 219-223.	3.9	6
229	Environmental chemical exposures among Greenlandic children in relation to diet and residence. International Journal of Circumpolar Health, 2019, 78, 1642090.	1.2	6
230	Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. Cardiovascular Drugs and Therapy, 2021, 35, 491-503.	2.6	6
231	Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A crossâ€over study. Clinical and Translational Science, 2021, 14, 2408-2419.	3.1	6
232	Cytochrome P450 2D6 genotypeâ€“phenotype characterization through population pharmacokinetic modeling of tedatioxetine. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 983-993.	2.5	6
233	Microdialysis as a tool to determine the local tissue concentration of dicloxacillin in man. British Journal of Clinical Pharmacology, 2018, 84, 533-541.	2.4	5
234	Using a semiâ€mechanistic model to identify the main sources of variability of metformin pharmacokinetics. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 105-114.	2.5	5

#	Article	IF	Citations
235	Development of Human Hair Reference Material Supporting the Biomonitoring of Methylmercury. Analytical Sciences, 2020, 36, 561-565.	1.6	5
236	No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 93-102.	2.5	5
237	Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. Nordic Journal of Psychiatry, 1993, 47, 85-89.	1.3	4
238	No Evidence for Taxane/Platinum Pharmacogenetic Markers: Just Lack of Power?. Journal of Clinical Oncology, 2008, 26, 1903-1904.	1.6	4
239	Is there interaction between tramadol and phenprocoumon?. Lancet, The, 1997, 350, 1552-1553.	13.7	3
240	Dose-Dependent Inhibition of the CYP2D6 Catalyzed Oxidation of Sparteine by Mepyramine in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 331-334.	0.0	3
241	Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2004, 54, 206-210.	3.0	3
242	Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department. Nordic Journal of Psychiatry, 2008, 62, 242-249.	1.3	3
243	The Impact of Serum Drug Concentration on the Efficacy of Imipramine, Pregabalin, and their Combination in Painful Polyneuropathy. Clinical Journal of Pain, 2017, 33, 1047-1052.	1.9	3
244	Secondary sex ratio in relation to exposures to polychlorinated biphenyls, dichlorodiphenyl dichloroethylene and methylmercury. International Journal of Circumpolar Health, 2017, 76, 1406234.	1.2	3
245	Use of Dicloxacillin and Risk of Pregnancy among Users of Oral Contraceptives. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 288-293.	2.5	3
246	Reference intervals for trace elements in the general Danish population and their dependence on serum proteins. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 523-531.	1.2	3
247	Professor Jens SÃ¸lver Schou 10 October 1929â€“8 March 2017. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 5-5.	2.5	2
248	Determinants of Chronic Biological Stress, Measured as Hair Cortisol Concentration, in a General Population of Adolescents: From Individual and Household Characteristics to Neighborhood Urbanicity. Frontiers in Public Health, 2021, 9, 669022.	2.7	2
249	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 1-2.	2.5	1
250	Professor Folke SjÃ¶qvist is the 2013 <scp>BCPT</scp> Nordic Prize Winner in Basic & Clinical Pharmacology & Toxicology. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 159-161.	2.5	1
251	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 3-4.	2.5	1
252	Professor Thue W. Schwartz is the BCPT Nordic Prize Winner 2017 in Basic & Clinical Pharmacology & Toxicology. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 5-6.	2.5	1

#	Article	IF	Citations
253	Professor Mats Karlsson is the BCPT Nordic Prize winner in Basic & Clinical Pharmacology & Toxicology for 2019. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 417-417.	2.5	1
254	Drug-drug cross contamination in the Swisslog fully automated medication handling system. European Journal of Hospital Pharmacy, 2021, 28, 229-230.	1.1	1
255	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 1-1.	2.5	0
256	BCPT Focused Nordic Conference. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 293-294.	2.5	0
257	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 361-361.	2.5	0
258	BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology for 2011 to Pertti J. Neuvonen. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 205-206.	2.5	0
259	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 1-1.	2.5	0
260	BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology for 2012 to Michael J. Mulvany. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 287-288.	2.5	0
261	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 1-1.	2.5	0
262	Professor Olavi Pelkonen is the 2014 <scp>BCPT</scp> Nordic Prize Winner in Basic and Clinical Pharmacology and Toxicology. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 145-146.	2.5	0
263	St. Johnâ€™s wort impairs Glucose tolerance by reducing insulin response in healthy Men. Clinical Therapeutics, 2015, 37, e9-e10.	2.5	0
264	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 1-1.	2.5	0
265	Philippe Grandjean is the 2015 <scp>BCPT</scp> Nordic Prize Awardee. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 123-125.	2.5	0
266	Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts. European Journal of Clinical Pharmacology, 2016, 72, 1159-1160.	1.9	0
267	The BCPT 2016 prize to Jan Alexander, Norway. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 3-4.	2.5	0
268	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 3-4.	2.5	0
269	Magnus Ingelmanâ€Sundberg is awarded the 2018 <scp>BCPT</scp> Nordic Prize in Basic and Clinical Pharmacology and Toxicology. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 643-644.	2.5	0
270	Preface. Advances in Pharmacology, 2018, 83, xv-xvi.	2.0	0

#	Article	IF	Citations
271	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 3-4.	2.5	0
272	Associations between liver PFAS concentrations and plasma extracellular miRNAs in a cohort of adolescents undergoing bariatric surgery. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
273	Severity of COVID-19 at elevated exposure to perfluorinated alkylates. , 2020, 15, e0244815.		0
274	Severity of COVID-19 at elevated exposure to perfluorinated alkylates. , 2020, 15, e0244815.		0
275	Severity of COVID-19 at elevated exposure to perfluorinated alkylates. , 2020, 15, e0244815.		0
276	Severity of COVID-19 at elevated exposure to perfluorinated alkylates. , 2020, 15, e0244815.		0